Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Reporter Cell Line Engineering

Active

Federal

Response Deadline06/24/2026, 04:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract involves the design and construction of engineered cell lines capable of reporting specific DNA modifications through the use of fluorescent or selectable markers. This work is intended to develop advanced biological tools that can detect and signal particular genetic changes within cells, enhancing the ability to study DNA modifications in a controlled and measurable manner. The project is categorized under the NAICS code 541714, which pertains to research and development in biotechnology. Issued by the Defense Advanced Research Projects Agency under the Department of Defense, this subcontract opportunity was posted in early May 2026, with responses due by late June 2026. Although specific details on the place of performance and points of contact are not provided, the focus is clearly on innovative molecular engineering to support defense-related biomedical research initiatives. This contract represents a specialized effort to push forward capabilities in genetic reporting and cellular engineering within high-tech bio-research environments.

General Info

Design and build engineered cell lines reporting DNA modifications using fluorescent/selectable markers.

Agency

Department Of Defense → Defense Advanced Research Projects Agcy

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

VA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedMay 6

subcontract

Response DeadlineJun 24

Submission deadline

Response Deadline

06/24/2026, 04:00:00 PM UTCin 8 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Defense → Defense Advanced Research Projects Agcy

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Design and construction of engineered cell lines that report specific DNA modifications via fluorescent or selectable markers.

Similar Contracts

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.

National Institutes Of Health

POSTED

about 21 hours ago

DEADLINE

in over 2 years

Scientific Data Analysis & Software Tool Development for JWSTThe contract involves the development and ongoing maintenance of software tools specifically designed for the calibration of NIRISS data, pipeline processing, and support of scientific operations related to the James Webb Space Telescope (JWST). This subcontract opportunity, issued by the National Research Council of Canada under the Government of Canada, seeks expertise in scientific data analysis and software tool development to enhance JWST's data handling capabilities. The work is to be performed in British Columbia and is associated with NAICS code 541714, indicating a focus on research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, with a response deadline of June 30, 2026. Although specific details such as set-aside types, organization type, or a direct point of contact are not provided, interested parties are encouraged to refer to the official tender notice link for more information. The contract emphasizes advanced software solutions to support scientific missions, ensuring the effective processing and analysis of space telescope data crucial for ongoing research.

National Research Council of Canada

POSTED

DEADLINE

International Agricultural Research Program DesignThe contract entails the design and structuring of a comprehensive international agricultural research program that aligns with the priorities of the Foreign Agricultural Service under the Department of Agriculture. It involves developing clear objectives, detailed methodologies, and expected outcomes aimed at advancing agricultural research on a global scale. The scope emphasizes strategic planning to address international agricultural challenges while supporting USDA-FAS goals to enhance trade, sustainability, and food security. This subcontract, carrying the NAICS code 541714, was posted on June 15, 2026, with a response deadline of August 14, 2026. While specific details such as the location of performance and contact information are not provided, the focus is on crafting a program that integrates scientific research with policy priorities to foster innovation and collaboration in international agriculture. The resulting program is expected to facilitate informed decision-making and promote economic opportunities within the global agricultural sector.

Foreign Agricultural Service

POSTED

DEADLINE

in about 2 months

TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.

Triad - DOE Contractor

POSTED

DEADLINE

Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.

Defense Health Agency

POSTED

DEADLINE